|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:academic_programs
|
gptkb:Dr._Alan_Brown
|
|
gptkbp:advertising
|
gptkb:Ms._Lisa_Blue
Mr. Tom Black
|
|
gptkbp:awards
|
Best Places to Work 2020
2021 Fierce Biotech Awards
2022 Top 10 Biotech Companies
|
|
gptkbp:ceo
|
Garrett J. Mc Carty
|
|
gptkbp:clinical_trial
|
NCT03614429
NCT04044859
NCT04202468
|
|
gptkbp:conducts_research_on
|
gptkb:Dr._John_Smith
|
|
gptkbp:focus
|
T cell therapies
|
|
gptkbp:founded
|
gptkb:2015
|
|
gptkbp:founder
|
gptkb:Michael_A._Haller
gptkb:Eric_B._Schmidt
gptkb:David_M._Hyman
Garrett J. Mc Carty
|
|
gptkbp:has_authority_over
|
Ms. Nancy Purple
|
|
gptkbp:head
|
gptkb:Mr._Steve_Gray
|
|
gptkbp:head_of_state
|
gptkb:Dr._Jane_Doe
gptkb:Dr._Richard_Roe
gptkb:Dr._Sarah_Green
Ms. Karen Yellow
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
TCR2 Therapeutics Inc.
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:investment
|
gptkb:New_Enterprise_Associates
gptkb:Canaan_Partners
gptkb:Orbi_Med_Advisors
|
|
gptkbp:key_people
|
gptkb:Michael_A._Haller
gptkb:Eric_B._Schmidt
gptkb:David_M._Hyman
|
|
gptkbp:number_of_employees
|
51-200
|
|
gptkbp:partnerships
|
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
gptkb:Novartis
|
|
gptkbp:products
|
gptkb:TCER-001
gptkb:TCER-002
|
|
gptkbp:regulatory_compliance
|
gptkb:Dr._Emily_White
|
|
gptkbp:research_focus
|
gptkb:Cell
cancer immunotherapy
T cell receptor engineering
|
|
gptkbp:stock_symbol
|
TCRR
|
|
gptkbp:subsidiaries
|
gptkb:TCR2_Therapeutics_Europe_Gmb_H
gptkb:TCR2_Therapeutics_Asia_Ltd.
TCR2 Therapeutics UK Ltd.
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.tcr2.com
|
|
gptkbp:bfsParent
|
gptkb:Ariad_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|